Summit Therapeutics (SUMM)


SUMM Share PerformanceMore

52 week high269.75 11/09/17
52 week low140.00 07/11/17
52 week change 17.00 (10.50%)
4 week volume524,283 27/12/17

Media for (SUMM)

Latest NewsMore

Summit Therapeutics to Present at the Biotech Showcase

Summit Therapeutics to Present at the Biotech Showcase Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT THE BIOTECH SHOWCASE Oxford, UK, 9 January 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for rare diseases ...

Summit in £10m antibiotics R&D deal

Summit Therapeutics is to pay 10m in cash and shares for Discuva whose principal asset is a genetics-based technology plat...

Acquisition of Discuva Ltd

Statement regarding an acquisition of a company or assets

Summit enters licence agreement in Latin America

Summit Therapeutics, a drug discovery and development company, has entered into an exclusive licence and commerciali...

Summit Enters Licence and Commercialisation Agreement with Eurofarma for Latin American Rights to Ridinilazole

Statement regarding a contract entered into/awarded/signed

Summit Therapeutics plc : 3rd Quarter Results

Third quarter and nine months financial results

Summit, Santhera, Catabasis and Duchenne UK to Host DMD Awareness Day

Summit schedules interim results announcement

Summit Therapeutics has confirmed that the Company intends to announce its third quarter and nine months results to 3...

Fundamental DataMore

Dividend yield0 %

Latest discussion posts More

  • Dilution

    So after todays press release all of the gain made following the previous press release has been wiped out in one foul swoop. It seems every time we get a decent rise in the ...
  • Re: NEW ARTICLE: Four AIM shares for a p...

    ps valid points raised. Sold these in two lots, 247 and 177 as could only see drift until 2018. C diff drug trying to break into an established market, always difficult ...
  • Re: NEW ARTICLE: Four AIM shares for a post-...

    The article referenced on Interactive Investor states that Summit Therapeutics has 2 potential treatments "both well down the road to becoming proven and commercial products". ...

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..

Codes & Symbols


Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account